ORMP, US68403P2039

Oramed Pharmaceuticals stock trades at USD 4.49 after insider sale

Published on 10/04/2026 at 12:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Oramed Pharmaceuticals stock has fresh insider-sale data from October 1, 2026, including a 30,000-share COO transaction. Market capitalization is USD 183.8 million, versus a 52-week high of USD 5.47.

ORMP, US68403P2039, Illustration mit AI erstellt.

Oramed Pharmaceuticals (ISIN US68403P2039) stood at USD 4.49 on Nasdaq at 4:00 p.m. ET on October 2, 2026, with a daily gain of 0.22 percent. The latest company-specific signal is insider selling disclosed after transactions dated October 1, 2026.

Two executives sell shares

According to MarketBeat on October 2, 2026, Chief Operating Officer Joshua Hexter sold 30,000 shares at an average USD 4.51 for USD 135,300. The transaction used a pre-arranged Rule 10b5-1 plan adopted on March 30, 2026, and left Hexter with 1,328,130 shares.

A second filing involved Chief Financial Officer Avraham Gabay, who sold 20,000 shares at an average USD 4.51 for USD 90,200 on October 1, 2026, according to MarketBeat. Gabay directly held 861,076 shares after the sale.

Stock stays below yearly high

ORMP has a 52-week range of USD 2.09 to USD 5.47. At USD 4.49, the stock sits 17.92 percent below its yearly high, giving investors a concrete measure of the rebound already priced into the shares.

Trading volume reached 178,321 shares on October 2, 2026, while the market capitalization stood at USD 183.8 million. The modest 0.22 percent session move contrasts with the larger distance from the yearly peak and keeps the insider transactions as the clearest near-term company signal.

Targets remain above the market

Fintel reported on September 15, 2026, that the average one-year price target had increased to USD 7.14 from USD 6.38. Its published target range was USD 7.07 to USD 7.35, placing the average target 59.02 percent above the October 2 reference price.

MarketBeat lists a Hold consensus based on one research report. That contrast between a higher published target and fresh executive selling makes the next reported operating update especially important for the small-cap biotechnology company.

Oramed Pharmaceuticals stock at USD 4.49

Oramed Pharmaceuticals stock closed at USD 4.49 on Nasdaq on October 2, 2026, up 0.22 percent for the session and 17.92 percent below its 52-week high of USD 5.47.